Akero Therapeutics Inc

1AKRO

Company Profile

  • Business description

    Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

  • Contact

    601 Gateway Boulevard
    Suite 350
    South San FranciscoCA94080
    USA

    T: +1 650 487-6488

    https://www.akerotx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    69

Stocks News & Analysis

stocks

New ASX share on our best ideas list

This undervalued miner is unappreciated by the market.
stocks

Has the most hated company on the ASX 200 bounced back?

Encouraging results indicate a potential turnaround story.
stocks

Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown

We think Amazon stock looks attractive.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,922.0077.00-0.86%
CAC 407,604.0057.840.77%
DAX 4023,621.64195.670.84%
Dow JONES (US)43,588.58542.40-1.23%
FTSE 1009,083.8848.93-0.54%
HKSE24,710.7862.55-0.25%
NASDAQ20,650.13472.31-2.24%
Nikkei 22540,290.70779.12-1.90%
NZX 50 Index12,684.04139.70-1.09%
S&P 5006,238.01101.38-1.60%
S&P/ASX 2008,663.7079.10-0.90%
SSE Composite Index3,583.3123.360.66%

Market Movers